# Bevacizumab in Treating Patients With Recurrent or Progressive Meningiomas

> **NCT01125046** · PHASE2 · COMPLETED · sponsor: **Northwestern University** · enrollment: 50 (actual)

## Conditions studied

- Acoustic Schwannoma
- Adult Anaplastic Meningioma
- Adult Ependymoma
- Adult Grade I Meningioma
- Adult Grade II Meningioma
- Adult Meningeal Hemangiopericytoma
- Adult Papillary Meningioma
- Neurofibromatosis Type 1
- Neurofibromatosis Type 2
- Recurrent Adult Brain Tumor

## Interventions

- **BIOLOGICAL:** bevacizumab

## Key facts

- **NCT ID:** NCT01125046
- **Lead sponsor:** Northwestern University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-06-17
- **Primary completion:** 2014-03-10
- **Final completion:** 2018-12-31
- **Target enrollment:** 50 (ACTUAL)
- **Last updated:** 2021-01-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01125046

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01125046, "Bevacizumab in Treating Patients With Recurrent or Progressive Meningiomas". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01125046. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*